Cardiovascular Adverse Events Associated with Smoking-Cessation Pharmacotherapies

Current Cardiology Reports

Volumn 17, Issue 1, 2015, Pages

  Sharma, Abhishek ^a,j   Thakar, Saurabh ^b   Lavie, Carl J ^c,d   Garg, Jalaj ^e   Krishnamoorthy, Parasuram ^f   Sochor, Ondrej ^g,h   Arbab Zadeh, Armin ⁱ   Lichstein, Edgar ^b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b MAIMONIDES MEDICAL CENTER   (United States)

^c JOHN OCHSNER HEART AND VASCULAR INSTITUTE   (United States)

^d PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

^f ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^g Mayo Clinic College of Medicine   (United States)

^h ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j NONE   (United States)

more..

Author keywords

Bupropion; Major adverse cardiovascular events; Myocardial infarction; Nicotine replacement therapy; Pharmacotherapies; Smoking cessation; Tachyarrhythmia; Varenicline

Indexed keywords

AMFEBUTAMONE; NICOTINE; PLACEBO; VARENICLINE; BENZAZEPINE DERIVATIVE; NICOTINIC AGENT; QUINOXALINE DERIVATIVE;

BEHAVIOR CHANGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEART PROTECTION; HIGH RISK POPULATION; HUMAN; INTERMETHOD COMPARISON; NICOTINE REPLACEMENT THERAPY; OUTCOME ASSESSMENT; PATIENT COUNSELING; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKING; SMOKING CESSATION; SYSTEMATIC REVIEW; WITHDRAWAL SEIZURE; CHEMICALLY INDUCED; DOSE RESPONSE; HYPERTENSION; PRACTICE GUIDELINE; PREVENTION AND CONTROL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEIZURE; TACHYCARDIA; THORAX PAIN;

BENZAZEPINES; BUPROPION; CHEST PAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERTENSION; NICOTINIC AGONISTS; PRACTICE GUIDELINES AS TOPIC; QUINOXALINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEIZURES; SMOKING; SMOKING CESSATION; TACHYCARDIA;

EID: 84923069679     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-014-0554-8     Document Type: Review

References (62)

1. Centers for Disease Control and Prevention. Health effects of cigarette smoking: fact sheet. 2014. http://www.cdc.gov/tobacco/data_statistics/fact_sheets/health_effects/effects_cig_smoking. Accessed 5 Jul 2014.
2. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction–executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004;44:671–719.
3. Jha P, Ramasundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN, et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med. 2013;368:341–50.
4. Wilson K, Gibson N, Willan A, Cook D. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med. 2000;160:939–44.
5. Glantz S, Gonzalez M. Effective tobacco control is key to rapid progress in reduction of non-communicable diseases. Lancet. 2012;379:1269–71.
6. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General: Office on Smoking and Health. Atlanta: Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion; 2006.
7. Fiore M, Jaen CR, Baker TB, Bailey WC, Bennett G, Benowitz NL, et al. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. public health service report. Clinical practice guideline treating tobacco use and dependence 2008 update panel, liaisons and staff. Am J Prev Med. 2008;35:158–76.
8. Hartmann-Boyce J, Stead LF, Cahill K, Lancaster T. Efficacy of interventions to combat tobacco addiction: Cochrane update of 2012 reviews. Addiction. 2013;108:1711–21.
9. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. The Cochrane database of systematic reviews. Cochrane Database Syst Rev. 2013;5:CD009329. This large overview/meta-analysis confirmed the efficacy of all three smoking cessation pharmacotherapies versus placebo and versus each other as quitting aids and demonstrated no significant excess of cardiovascular events in users of all three treatments.
10. Glover ED, Glover PN, Payne TJ. Treating nicotine dependence. Am J Med Sci. 2003;326:183–6.
11. Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA. 1994;271:1940–7.
12. US Department of Health and Human Services, Public Health Services, Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence: clinical practice guideline. Rockville: US Dept of Health and Human Services, Public Health Service; 2000. p. 25–90.
13. Blann AD, Steele C, McCollum CN. The influence of smoking and of oral and transdermal nicotine on blood pressure, and haematology and coagulation indices. Thromb Haemost. 1997;78:1093–6.
14. Lucini D, Bertocchi F, Malliani A, Pagani M. Autonomic effects of nicotine patch administration in habitual cigarette smokers: a double-blind, placebo-controlled study using spectral analysis of RR interval and systolic arterial pressure variabilities. J Cardiovasc Pharmacol. 1998;31:714–20.
15. Zevin S, Jacob 3rd P, Benowitz NL. Dose-related cardiovascular and endocrine effects of transdermal nicotine. Clin Pharmacol Ther. 1998;64:87–95.
16. Mundal HH, Hjemdahl P, Gjesdal K. Acute effects of low dose nicotine gum on platelet function in non-smoking hypertensive and normotensive men. Eur J Clin Pharmacol. 1995;47:411–6.
17. Benowitz NL, Fitzgerald GA, Wilson M, Zhang Q. Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking. J Am Coll Cardiol. 1993;22:1159–67.
18. Tzivoni D, Keren A, Meyler S, Khoury Z, Lerer T, Brunel P. Cardiovascular safety of transdermal nicotine patches in patients with coronary artery disease who try to quit smoking. Cardiovasc Drugs Ther. 1998;12:239–44.
19. Keeley EC, Pirwitz MJ, Landau C, Lange RA, Hillis LD, Foerster EH, et al. Intranasal nicotine spray does not augment the adverse effects of cigarette smoking on myocardial oxygen demand or coronary arterial dimensions. Am J Med. 1996;101:357–63.
20. Nitenberg A, Antony I. Effects of nicotine gum on coronary vasomotor responses during sympathetic stimulation in patients with coronary artery stenosis. J Cardiovasc Pharmacol. 1999;34:694–9.
21. Mall T, Grossenbacher M, Perruchoud AP, Ritz R. Influence of moderately elevated levels of carboxyhemoglobin on the course of acute ischemic heart disease. Respiration. 1985;48:237–44.
22. Palmer KJ, Buckley MM, Faulds D. Transdermal nicotine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs. 1992;44:498–529.
23. Mahmarian JJ, Moye LA, Nasser GA, Nagueh SF, Bloom MF, Benowitz NL, et al. Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. J Am Coll Cardiol. 1997;30:125–30.
24. Ford CL, Zlabek JA. Nicotine replacement therapy and cardiovascular disease. Mayo Clin Proc. 2005;80:652–6.
25. Ottervanger JP, Festen JM, de Vries AG, Stricker BH. Acute myocardial infarction while using the nicotine patch. Chest. 1995;107:1765–6.
26. Ropchan GV, Sanfilippo AJ, Ford SE. Aortic dissection and use of the nicotine patch: a case involving a temporal relationship. Can J Cardiol. 1997;13:525–8.
27. Van der Klauw MM, Van Hillo B, Van den Berg WH, Bolsius EP, Sutorius FF, Stricker BH. Vasculitis attributed to the nicotine patch (Nicotinell). Br J Dermatol. 1996;134:361–4.
28. Dacosta A, Guy JM, Tardy B, Gonthier R, Denis L, Lamaud M, et al. Myocardial infarction and nicotine patch: a contributing or causative factor? Eur Heart J. 1993;14:1709–11.
29. Pierce Jr JR. Stroke following application of a nicotine patch. Ann Pharmacother. 1994;28:402.
30. Warner Jr JG, Little WC. Myocardial infarction in a patient who smoked while wearing a nicotine patch. Ann Intern Med. 1994;120:695.
31. Riche G, Nighoghossian N, Trouillas P. Intracerebral haematoma after application of nicotine patch. Lancet. 1995;346:777–8.
32. Mathew TP, Herity NA. Acute myocardial infarction soon after nicotine replacement therapy. QJM. 2001;94:503–4.
33. Working group for the study of transdermal nicotine in patients with coronary artery disease. Nicotine replacement therapy for patients with coronary artery disease. Arch Intern Med. 1994;154:989–95.
34. Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996;335:1792–8.
35. Mills EJ, Wu P, Lockhart I, Wilson K, Ebbert JO. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. Tob Induc Dis. 2010;8:8.
36. Haustein KO, Krause J, Haustein H, Rasmussen T, Cort N. Comparison of the effects of combined nicotine replacement therapy vs. cigarette smoking in males. Nicotine Tob Res. 2003;5:195–203.
37. Greenland S, Satterfield MH, Lanes SF. A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Saf. 1998;18:297–308.
38. Kimmel SE, Berlin JA, Miles C, Jaskowiak J, Carson JL, Strom BL. Risk of acute first myocardial infarction and use of nicotine patches in a general population. J Am Coll Cardiol. 2001;37:1297–302.
39. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Rockville, MD: Department of Health and Human Services, Public Health Service, Office of Surgeon General; 2010.
40. Mills EJ, Thorlund K, Eapen S, Wu P, Prochaska JJ. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation. 2014;129:28–41. This was a major large meta-analysis of electronic databases, RCTs, and US FDA reports, which showed that smoking cessation therapies do not appear to raise the risk of serious cardiovascular disease events, except for use in smokers hospitalized for ST-segment-elevation myocardial infarction, which needs further study
41. Gourlay SG, Forbes A, Marriner T, McNeil JJ. Predictors and timing of adverse experiences during trandsdermal nicotine therapy. Drug Saf. 1999;20:545–55.
42. Rigotti NA, Thorndike AN, Regan S, McKool K, Pasternak RC, Chang Y, et al. Bupropion for smokers hospitalized with acute cardiovascular disease. Am J Med. 2006;119:1080–7.
43. Tonstad S, Farsang C, Klaene G, Lewis K, Manolis A, Perruchoud AP, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J. 2003;24:946–55.
44. Roose SP. Considerations for the use of antidepressants in patients with cardiovascular disease. Am Heart J. 2000;140(4 Suppl):84–8.
45. Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EG. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry. 1991;148:512–6.
46. Beyens MN, Guy C, Mounier G, Laporte S, Ollagnier M. Serious adverse reactions of bupropion for smoking cessation: analysis of the French Pharmacovigilance Database from 2001 to 2004. Drug Saf. 2008;31:1017–26.
47. Issa JS, Perez GH, Diament J, Zavattieri AG, de Oliveira KU. Effectiveness of sustained-release bupropion in the treatment of smoker patients with cardiovascular disease. Arq Bras Cardiol. 2007;88:434–40.
48. Perkins KA. Smoking cessation in women. Special considerations. CNS Drugs. 2001;15:391–411.
49. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology. 2007;52:985–94.
50. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2011;16, CD006103.
51. Ari H, Celiloglu N, Ari S, Cosar S, Doganay K, Bozat T. The effect of varenicline on heart rate variability in healthy smokers and nonsmokers. Auton Neurosci. 2011;164:82–6.
52. Wang J, Wang X, Irnaten M, Venkatesan P, Evans C, Baxi S, et al. Endogenous acetylcholine and nicotine activation enhances GABAergic and glycinergic inputs to cardiac vagal neurons. J Neurophysiol. 2003;89:2473–81.
53. Benowitz NL. Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis. 2003;46:91–111.
54. Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ. 2011;183:1359–66.
55. Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ. 2012;344:e2856.
56. Harrison-Woolrych M, Maggo S, Tan M, Savage R, Ashton J. Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand. Drug Saf. 2012;35:33–43.
57. Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010;121:221–9.
58. FDA Drug Safety Communication. Chantix (varenicline) may increase the risk of certain cardiovascular adverse events in patients with cardiovascular disease Issued 22 July 2011. http://www.fda.gov/Drugs/Drugsafety/ucm259161.htm. Accessed 5 Jul 2014.
59. US Food and Drug Administration. FDA drug safety communication: safety review update of Chantix (Varenicline) and risk of cardiovascular adverse events. http://www.fda.gov/drugs/drugsafety/ucm330367.htm. Accessed 5 Jul 2014.
60. Toh S, Baker MA, Brown JS, Kornegay C, Platt R, Mini-Sentinel I. Rapid assessment of cardiovascular risk among users of smoking cessation drugs within the US Food and Drug Administration’s Mini-Sentinel program. JAMA Intern Med. 2013;173:817–9. This was a recent FDA mini-sentinel evaluation of CVD events that found no difference in CVD event risk between varenicline and bupropion users
61. Svanstrom H, Pasternak B, Hviid A. Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. BMJ. 2012;345:e7176. This was a large, nationwide, observational cohort study that found no increased risk of major cardiovascular events associated with the use of varenicline compared with bupropion for smoking cessation
62. Hajek P, McRobbie H, Myers K. Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis. Thorax. 2013;68(11):1037–42.